louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02643537: Associated Pathologies Following Luxatio Erecta Humeri: A Retrospective Analysis of 31 Cases and Diagnostic Algorithm
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Shoulder Dislocation
Lead sponsor: Medical University of Vienna
Sponsor class: OTHER
First posted: 2015-12-31
Enrollment: 31
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Included for analysis were thirty-one patients (11 females (average age 68.2 years) and 20 males (average age 48.3 years)) who have been treated for Laxation erecta between 1992 and 2015.

Brief summary: The aim of this study was to evaluate the clinical outcome of this rare injury with special emphasis on associated pathologies. Additionally, we aimed to develop an algorithm for the diagnosis of associated pathologies following LEH.


Eligibility criteria: Inclusion Criteria:

* Included for analysis were all patients over 18 years of age who have been treated for LEH between at our department.

Exclusion Criteria:

* Only injuries of the affected shoulder were taken into account, non-shoulder related pathologies were not addressed.
* Other types of shoulder dislocation except Luxatio erecta

Primary outcomes:
measure: Functional clinical outcome
timeFrame: at least 2months
Secondary outcomes:
measure: ASSOCIATED PATHOLOGIES
timeFrame: at least 2 months
measure: Pain
timeFrame: at least 2 months
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00320437: Intergenerational Transmission of Terror
Official title: The Intergenerational Transmission of Trauma From Terror: A Developmental Perspective
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Anxiety
Trauma
Stress Disorders
Keywords: trauma
anxiety
antenatal
mothers
children
Gene x Environment Interaction
Lead sponsor: Hadassah Medical Organization
Sponsor class: OTHER
First posted: 2006-05-03
Enrollment: 300
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: DEFINED_POPULATION
Time perspective: PROSPECTIVE

Brief summary: Our aim is examine avenues by which mothers can transmit their trauma to their children.

Detailed description: The goal of the study is to test for genetic bases and Gene x Environment interactions on the development of difficulties, particularly stress disorders, in young children whose mother were exposed to terror before they were born.

Eligibility criteria: Inclusion Criteria:

* Pregnant women who were exposed to terror in the last 5 years
* Matched Controls

Exclusion Criteria:

* Does not speak Hebrew or English

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Jerusalem
country: Israel
facility: Hadassah University Hospital
state: Ein Kerem
Study officials:
affiliation: State University of New York - Upstate Medical University
name: Steven Faraone, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03179137: Mitochondrial Bioenergetics and Role in Cellular Damage in Ischemic Myocardium
Official title: Pathophysiological Mechanisms Elicited by Ischemia and Metabolic Co-morbidities in Myocardium of Patients With Coronary Artery Disease
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Coronary Artery Disease
Diabetes Mellitus
Mitochondrial Metabolism Disorders
Lead sponsor: University of Split, School of Medicine
Sponsor class: OTHER
First posted: 2017-06-07
Enrollment: 80
Sex: ALL
Minimum age (years): 50
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Hemodynamically stable patients with coronary artery disease diagnosed with angiography with indication for coronary artery bypass grafting surgery

Brief summary: Cardiac ischemia is a common pathological condition, known to elicit multiple pathological processes at the cellular level. One of the most affected is thought to be cellular metabolism, key for the adequate cardiac function. The aim is to study mitochondrial bioenergetic function, interaction with other cellular systems and influence of several co-morbidities in myocardium of the affected patients.

Detailed description: Coronary artery disease, one of the most common pathologies in the developed world, causes hypoperfusion of myocardial tissue, usually evident by the presence of anginal pain. This myocardial ischemia elicits alterations in normal cardiomyocyte physiology, which gradually deteriorate cellular function, affecting the performance of the entire organ. The condition is frequently further complicated (and aggravated) by the presence of various co-morbidities, such as diabetes mellitus. The primary aim of this study is to investigate the cardiomyocyte bioenergetics and the consequences of potentially reduced mitochondrial metabolic function in ischemic heart, and evaluate the potential contribution of other conditions, primarily ones affecting metabolic homeostasis.

Eligibility criteria: Inclusion Criteria:

* Coronary artery disease
* Indication for coronary artery bypass grafting surgery

Exclusion Criteria:

* Emergency patients
* Patients with LV ejection fraction (LVEF) below 30%
* Patients with severe renal, hepatic or pulmonary disease

Primary outcomes:
measure: Mitochondrial oxygen consumption (rate of oxygen consumption per milligram of left ventricular tissue)
timeFrame: 2016-2020
measure: Myocardial production of reactive oxygen species
timeFrame: 2016-2020
Secondary outcomes:
measure: Anti-cardiolipin antibodies in the blood of patients with symptoms of cardiac ischemia
timeFrame: 2016-2020
Other outcomes:
Locations:
city: Split
country: Croatia
facility: School of Medicine, University of Split
Study officials:
References:
Clinical trial NCT02323737: Phase II Study of Irinotecan and Cisplatin in Extensive-stage Small Cell Lung Cancer
Official title: Cisplatin Combined With Irinotecan or Etoposide for Untreated Extensive-stage Small Cell Lung Cancer: a Multicenter Randomized Control Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Extensive-stage Small Cell Lung Cancer
Lead sponsor: ChineseAMS
Sponsor class: UNKNOWN
Collaborators: name: China-Japan Friendship Hospital
name: Chinese PLA General Hospital
First posted: 2014-12-23
Enrollment: 62
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Patients with untreated extensive-stage small cell lung cancer(SCLC) were randomly assigned to receive either irinotecan/cisplatin (IP) or etoposide/cisplatin(EP), The association of efficacy and toxicity of IP regimen was analyzed.

Detailed description: This is a randomized, multicenter study. Patients are randomized to irinotecan/cisplatin (IP) or etoposide/cisplatin (EP) treatment arms. The IP regimen consisted of at most 6 cycles of irinotecan 65 mg/m2 of body-surface area on days 1, 8 and cisplatin 75mg/m2 of body-surface area on day 1. The EP regimen consisted of at most 6 cycles of etoposide 100 mg/m2 of body-surface area from day 1 to 3 and cisplatin 75mg/m2 of body-surface area on day 1. Cycle length for the two arms was 3 weeks. The dose adjustment was allowed in at most within ±5% per investigator discretion if necessary.

Eligibility criteria: Inclusion Criteria:

* Eastern Cooperative Oncology Group (ECOG) of 0 to 2
* A life expectancy of at least 3 months
* Measurable lesions
* Adequate hematologic function

Exclusion Criteria:

* Infection
* Myocardial infarction within the preceding three months
* Symptomatic brain metastases or receiving radiotherapy less than 4 weeks
* Pregnancy or breast-feeding

Primary outcomes:
measure: progression-free survival
timeFrame: 1 month
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
state: Beijing
Study officials:
affiliation: Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
name: yuankai shi, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
name: xingsheng Hu
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03787537: Nutritional Status and Nutrient Supply in Hospitalised Surgical Patients
Official title: Assessing Nutritional Status and Nutrient Supply in Hospitalised Patients Undergoing Major Abdominal Surgery of the Gastrointestinal Tract
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Colorectal Cancer
Esophageal Cancer
Gastric Cancer
Keywords: Nutrition
Surgery
Lead sponsor: Charite University, Berlin, Germany
Sponsor class: OTHER
First posted: 2018-12-26
Enrollment: 128
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Elective surgical patients

Brief summary: Prospective single arm, single center observational study to assess the nutritional status and the nutrient supply during hospitalization for elective gastrointestinal surgery.


Eligibility criteria: Inclusion Criteria:

* patients undergoing elective surgery of the upper or lower gastrointestinal tract
* mental and verbal ability to understand, read and write in German language
* written informed consent for study participation

Exclusion Criteria:

* age \<18 years
* inadequate ability to be compliant with the study protocol or to complete documentation for the Food frequency questionnaires

Primary outcomes:
measure: Change in nutritional status
timeFrame: 24 hours pre-surgery and 7 days after surgery
Secondary outcomes:
measure: Energy intake
timeFrame: 1 day before surgery, the day of surgery and up to 7 days after surgery
measure: Change in plasma amino acid levels
timeFrame: 24 hours pre-surgery up to 7 days after surgery
measure: Change in beta-hydroxybutyrate levels
timeFrame: 24 hours pre-surgery up to 7 days after surgery
measure: Change in free fatty acid levels
timeFrame: 24 hours pre-surgery up to 7 days after surgery
measure: Change in triacylglycerides levels
timeFrame: 24 hours pre-surgery up to 7 days after surgery
measure: Change in low density lipoprotein levels
timeFrame: 24 hours pre-surgery up to 7 days after surgery
measure: length of hospital stay
timeFrame: 14 days
Other outcomes:
Locations:
city: Berlin
country: Germany
facility: Charité - Universitätsmedizin Berlin
Study officials:
References:
Clinical trial NCT01654237: Musculoskeletal Complaints in an Industry
Official title: Factors That Influence the Prevalence of Musculoskeletal Complaints Among Workers in Different Sectors of an Industry
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Musculoskeletal Disorder
Keywords: work
WMSD
prevalence
occupational risks
industry
questionnaires
musculoskeletal pain
lifestyle
Lead sponsor: University of Sao Paulo General Hospital
Sponsor class: OTHER
Collaborators: name: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.
First posted: 2012-07-31
Enrollment: 185
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The hypothesis of this study is that there will be a variety of factors influencing the musculoskeletal complaints among workers of different sectors.

Work-related musculoskeletal disorders (WMSDs) account for more than 30% of occupational diseases in the world. In order to organize the strategic actions that will be developed for the prevention of MSDs, it is essential to analyze in advance the peculiar situations of the different sectors of a workplace. The objectives of this study were to determine the prevalence of musculoskeletal complaints among workers in a medium-sized industry by comparing its sectors and to investigate the influence of occupational and non-occupational factors in the increase of complaints.

Detailed description: The Nordic questionnaire was used to asses musculoskeletal symptoms as well as questionnaires about lifestyle and work-related conditions in 185 workers divided into three sectors of an industry (factory - microelectronics, office and logistics)

Eligibility criteria: Inclusion Criteria:

* work in the industry

Exclusion Criteria:

* work less than a month in the industry

Primary outcomes:
measure: musculoskeletal complaints
timeFrame: one month
Secondary outcomes:
Other outcomes:
Locations:
city: Sao Paulo
country: Brazil
facility: Faculty of Medicine. University of Sao Paulo
state: Sao Paulo/SP
Study officials:
affiliation: Faculty of Medicine. University of Sao Paulo
name: Denise Harari, post grad
role: PRINCIPAL_INVESTIGATOR
affiliation: Faculty of Medicine. University of Sao Paulo
name: Raquel A Casarotto, doctor
role: STUDY_DIRECTOR
References:
Clinical trial NCT04012437: Efficacy of App and Electronic Device in the Treatment of Premature Ejaculation
Official title: Sphincter Control Training Program Using a App and Electronic Medical Device in the Treatment of Premature Ejaculation: Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Premature Ejaculation
Masturbation
Medical Device
Keywords: Premature ejaculation
IELT
Medical device
Lead sponsor: Instituto Sexológico Murciano
Sponsor class: OTHER
Collaborators: name: Hospital Virgen del Alcazar de Lorca
First posted: 2019-07-09
Enrollment: 40
Sex: MALE
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Randomized control trial
Primary purpose: TREATMENT

Brief summary: Randomized control trial to determine if we can produce increases in the IELT using a new masturbator electronic in subjects with premature ejaculation in combination with a exercise app, producing improvements in the quality and satisfaction of the sexuality of the patient.

Detailed description: This project of research will use one experimental groups, It will manage the affairs the therapy "sphincter control training" (SCT) into app combined with the external device called Myhixel I .Experimental groups will receive therapy with the protocol of exercises SCT.

The main measure will be the "fold increase" (FI) of the IELT, which was calculated using the geometric mean of post-treatment IELTs (period B) divided by the geometric mean of pre-treatment IELTs (period A): FI = (geometric mean of IELT_7wk)/(geometric mean of PRE_IELT)

The efficiency on the EP will see (IELT) reflected in an increase in the times of latency of intravaginal ejaculation and in punctuations of subjective perception, of the therapy on the line base.

The subjects that will be born in mind will be all the interested parties in informing that their answer to the campaign of national advertising that will be started.

The duration of the treatment will be 8 weeks during which a series of exercises app will be practised usin the masturbation device Myhixel I.

The material used in the research will be innocuous and his responsible use does not produce adverse reactions of interest.

Eligibility criteria: Inclusion Criteria:

* Aged over 18 years.
* Being in a heterosexual relationship for at least the last 6 months.
* Having a score of \>11 on the Premature Ejaculation Diagnostic Tool (PEDT).
* Having a self-reported IELT ≤2 minutes.

Exclusion Criteria:

* A history of alcohol abuse or dependence.
* Having received medication or psychological treatment for PE in the last 6 months.
* Having diabetes.
* The regular use of recreational drugs (except tobacco and caffeine).

Primary outcomes:
measure: IELT FOLD INCREASE
timeFrame: 10 weeks
Secondary outcomes:
measure: PEDT
timeFrame: 10 weeks
Other outcomes:
Locations:
city: Murcia
country: Spain
facility: Jesús Rodríguez
Study officials:
References:
Clinical trial NCT02170337: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 282 in Healthy Subjects and Subjects With Chronic Rhinosinusitis With Nasal Polyps
Official title: A Randomized, Double-blind, Placebo-controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 282 in Healthy Subjects and Subjects With Chronic Rhinosinusitis With Nasal Polyps
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Chronic Rhinosinusitis With Nasal Polyps
Lead sponsor: Amgen
Sponsor class: INDUSTRY
First posted: 2014-06-23
Enrollment: 41
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: A randomized, double-blind, ascending multiple dose study in healthy volunteers and subjects with chronic rhinosinusitis with nasal polyps


Eligibility criteria: Healthy Volunteers:

Inclusion Criteria:

* Healthy males and females witha BMI between 18.0 and 32.0 kg/m2, inclusive

Exclusion Criteria:

* subject with evidence of a clinically significant disorder, condition or disease that would pose a risk to subject safety or interfere with study evaluation, procedures, or completion.

Subjects with chronic rhinosinusitis with nasal polyps (CRSwNP):

Inclusion Criteria:

* diagnosis of CRSwNP (inflammation of the nose and paranasal sinuses characterized in adults by 2 or more symptoms, 1 of which should be either nasal blockage or nasal discharge and/or facial pain and/or reduced smell for greater than 12 weeks)
* bilateral nasal polyps of grade 3 or 4

Exclusion Criteria:

* Forced Expiratory Volume (FEV1) \</= 70%
* Asthma exacerbation requiring systemic corticosteroid treatment or hospitalization for \> 24h for treatment of asthma, within 3 months prior to screening or are on a dose of greater than 1000 μg fluticasone.

Primary outcomes:
measure: Safety and tolerability
timeFrame: 169 days
measure: Immunogenicity
timeFrame: 169 days
Secondary outcomes:
measure: Pharmacokinetic profile of AMG 282
timeFrame: 169 days
Other outcomes:
Locations:
city: Santa Monica
country: United States
facility: Research Site
state: California
city: Aurora
country: United States
facility: Research Site
state: Colorado
city: South Miami
country: United States
facility: Research Site
state: Florida
city: Houston
country: United States
facility: Research Site
state: Texas
Study officials:
affiliation: Amgen
name: MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT04119037: Cordotomy in Reducing Pain in Patients With Advanced Cancer
Official title: Percutaneous Cordotomy for Pain Palliation in Advanced Cancer
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Advanced Malignant Neoplasm
Lead sponsor: M.D. Anderson Cancer Center
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
name: National Institute of Nursing Research (NINR)
First posted: 2019-10-08
Enrollment: 27
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This trial studies how well cordotomy works in reducing pain in patients with cancer that has spread to other places in the body (advanced). Cordotomy is performed on the spinal cord with a needle and guided by computed tomography scans and is designed to help reduce pain. This study is being done to learn if a cordotomy reduces pain in patients with unmanageable cancer pain.

Detailed description: PRIMARY OBJECTIVES:

I. Assess the efficacy of cordotomy for patients with unilateral advanced cancer pain.

SECONDARY OBJECTIVES:

I. Define the patient experience of cordotomy for cancer pain refractory to palliative care.

II. Determine whether magnetic resonance imaging (MRI) can be used as a noninvasive biomarker for a successful cordotomy.

OUTLINE: Patients are randomized to 1 of 2 groups.

GROUP I: Patients undergo a cordotomy over 1-2 hours.

GROUP II: Patients receive morphine via injection into the spine and undergo a fake cordotomy over 1-2 hours.

After completion of study, patients are followed up at 2 weeks and once every month for up to 6 months.

Eligibility criteria: Inclusion Criteria:

* Ability to provide informed consent
* Has undergone 3 palliative care evaluations
* Pain intensity \>= 4 on a 0-10 numerical scale
* Unilateral pain due to cancer below the shoulder level (arm, trunk, hip, leg)

Exclusion Criteria:

* Uncorrectable coagulopathy
* Large intracranial mass
* Inability to complete assessment forms
* Life expectancy \< 1 month
* Contraindication to intravenous sedation
* Morphine allergy

Primary outcomes:
measure: Reduction in pain intensity
timeFrame: Up to 6 months
Secondary outcomes:
measure: Brief Pain Inventory pain interference items
timeFrame: Up to 6 months
measure: Other ESAS symptoms
timeFrame: Up to 6 months
Other outcomes:
Locations:
city: Houston
country: United States
facility: M D Anderson Cancer Center
state: Texas
Study officials:
affiliation: M.D. Anderson Cancer Center
name: Eduardo Bruera
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02460952: The Clinic Study to Prevent Pulmonary Embolism in Patients With General Anesthesia Operation in Perioperative Period
Official title: The Clinic Study to Prevent Pulmonary Embolism in Patients With General Anesthesia Operation in Perioperative Period
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Pulmonary Embolism
Keywords: Pulmonary Embolism;
perioperative period;
general anesthesia
Lead sponsor: Beijing Chao Yang Hospital
Sponsor class: OTHER
First posted: 2015-06-03
Enrollment: 500
Sex: ALL
Minimum age (years): 45
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients accept Operation with general anesthesia

Brief summary: The purpose of this study is to investigate the prevention of Pulmonary Embolism in Patients who With General Anesthesia Operation in Perioperative Period.

Detailed description: Patients who received general anesthesia operation in Beijing Chaoyang Hospital affiliated to Capital Medical University were collected. The incidence of pulmonary embolism in perioperative period and age, gender,the surgery , clinical stage, clinical efficacy assessment will be further analyzed.

Eligibility criteria: Inclusion Criteria:

* The first time to accept the general anesthesia operation

Exclusion Criteria:

* Pregnancy.
* The function of liver and kidney disorder or serious abnormal electrolyte.
* The abnormal coagulation dysfunction and blood volume.

Primary outcomes:
measure: The changes of patients'Lower extremity vein in perioperative period of general anesthesia operation
timeFrame: 3 days before operation to 7 days after the operation
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Liu Sijie
state: Beijing
Study officials:
affiliation: Vice president of Beijing Chaoyang Hospital
name: yingmin ma, doctor
role: STUDY_DIRECTOR
References: